Evince Biosciences is focused on drug discovery and cancer immunotherapy.

Our core technology (AVO – Autonomous Virtual Organism) predicts activity (not binding) of small molecules against a target and, in parallel, determines drug-like characteristics such as human intestinal absorption, ability to cross the blood brain barrier, plasma protein binding, etc. In this way, AVO addresses activity, selectivity and ADMET in parallel. Once a drug-like lead is found, AVO is used to design medicinal chemistry approaches.

Evince has a lead cancer immunotherapy program and several additional targets “trained” in the AVO system so that an oncology pipeline can be established. The lead program is expected to reach an IND in 18-24 months.

We are in the process of raising money and partnering and are interested in discussions to address either goal (or both).